Predictors of antitumor necrosis factor primary nonresponse and drug durability in pediatric inflammatory bowel disease.

ABSTRACT:

Objectives

Antitumor necrosis factor (anti-TNF) therapies are first-line therapies for children with inflammatory bowel disease (IBD) (Crohn's disease [CD], ulcerative colitis [UC] and IBD-unclassified [IBD-U]). Limited studies describing anti-TNFs durability and loss of response in children. This study evaluates predictors of primary Nonresponse and 3-year drug durability in children with IBD.

Methods

This was a single-center retrospective review of patients with IBD less than 18 years old who initiated anti-TNF (infliximab or adalimumab) from January 1, 2014, to December 31, 2019. Clinical and laboratory data were recorded at the time of anti-TNF initiation, 14 weeks, 12 months, and 3 years. Predictors of primary nonresponse (discontinuation within 14 weeks) and durability

SUBMITTER: Davidson N 

PROVIDER: S-EPMC12539775 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature